Recent News

• 08.04.2026 - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
• 07.23.2026 - Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
• 06.18.2026 - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
• 05.18.2026 - Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
• 05.13.2026 - Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
• 05.12.2026 - Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
• 05.07.2026 - Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
• 04.01.2026 - Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
• 03.25.2026 - Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
• 02.24.2026 - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Recent Filings

• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 07.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.27.2026 - 144 Report of proposed sale of securities
• 07.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.30.2026 - 144 Report of proposed sale of securities
• 06.29.2026 - 144 Report of proposed sale of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities